Provided by Tiger Trade Technology Pte. Ltd.

Jasper Therapeutics

1.86
+0.14008.14%
Post-market: 1.83-0.0300-1.61%19:33 EST
Volume:1.22M
Turnover:2.27M
Market Cap:52.05M
PE:-0.32
High:1.92
Open:1.73
Low:1.71
Close:1.72
52wk High:22.99
52wk Low:1.39
Shares:27.98M
Float Shares:22.81M
Volume Ratio:2.06
T/O Rate:5.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.7868
EPS(LYR):-4.8865
ROE:-191.12%
ROA:-72.92%
PB:4.50
PE(LYR):-0.38

Loading ...

Jasper Therapeutics Advances Briquilimab Study for Chronic Urticaria

TIPRANKS
·
Oct 28

Jasper Therapeutics Highlights Promising Briquilimab Data in Chronic Urticaria and Other Inflammatory Diseases in Latest Corporate Presentation

Reuters
·
Oct 14

Director Svetlana Lucas Reports Acquisition of Common Shares of Jasper Therapeutics Inc

Reuters
·
Sep 25

Jasper Therapeutics price target lowered to $6 from $12 at Citizens JMP

TIPRANKS
·
Sep 22

Jasper Therapeutics Is Maintained at Buy by BTIG

Dow Jones
·
Sep 22

U.S. RESEARCH ROUNDUP-Apple, GE Aerospace, Tesla

Reuters
·
Sep 22

Jasper Therapeutics Inc : Btig Cuts Target Price to $7 From $20

THOMSON REUTERS
·
Sep 22

BTIG Remains a Buy on Jasper Therapeutics (JSPR)

TIPRANKS
·
Sep 20

Jasper Therapeutics Announces $30 Million Public Offering

TIPRANKS
·
Sep 20

Jasper Therapeutics 11.67M share Spot Secondary priced at $2.43

TIPRANKS
·
Sep 19

Jasper Therapeutics Plans Public Offering of Securities

MT Newswires Live
·
Sep 19

Jasper Therapeutics Shares Down 9.7% After the Bell; Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

THOMSON REUTERS
·
Sep 19

Jasper Therapeutics Inc - Proceeds to Advance Briquilimab Development and Corporate Purposes

THOMSON REUTERS
·
Sep 19

Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

GlobeNewswire
·
Sep 19

Jasper Therapeutics Inc. Unveils Presentation on Briquilimab's Efficacy and Safety in Chronic Urticaria

Reuters
·
Sep 03

Health Rounds: Experimental Jasper drug helps stem cell transplant patients avoid toxic chemotherapy in tiny trial

Reuters
·
Aug 27

Jasper Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
Aug 15

UBS Cuts Price Target on Jasper Therapeutics to $25 From $29, Maintains Buy Rating

MT Newswires Live
·
Aug 15

Jasper Therapeutics Q2 EPS $(1.74) Misses $(1.40) Estimate

Benzinga
·
Aug 14

Jasper Therapeutics Reports Q2 2025 Net Loss of $26.7 Million and EPS Loss of $1.74

Reuters
·
Aug 14